Market Analysis: Global Smith-Lemli-Opitz Syndrome Market

Global Smith-Lemli-Opitz syndrome market is expected to grow at a steady CAGR in the forecast period of 2019-2026. Increase in demand of targeted mode of therapies and high unmet need of treatment are the key factors for growth of this market.

Market Definition: Global Smith-Lemli-Opitz Syndrome Market

Smith-Lemli-Opitz Syndrome (SLOS) is also known as Rutledge lethal multiple congenital anomaly syndromes are rare developmental disorder characterized by multiple congenital anomalies, learning problems and behavioral problems. It is caused by mutation in the DHCR7 (7-dehydrocholesterol reductase) gene which codes for an enzyme that is involved in the secretion of cholesterol in the brain. People with Smith-Lemli-Opitz syndrome are unable to make enough cholesterol as they should in the brain to support normal growth and development and eventually leads to develop neuropsychiatric and neurodevelopmental symptoms.

According to the source from National Organization for Rare Disorders, Inc, an estimated annual prevalence of Smith-Lemli-Opitz syndrome is approximately 1 in 20,000 to 60,000 live births in the United States. Presence of refined healthcare infrastructure and high demand of disease specific novel therapies are the key factors that fueling the market growth

Market Drivers

Huge financial support to the researchers for developing novel intervention is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver
Emergence of drug used in the treatment of complications associated with Smith-Lemli-Opitz syndrome
High unmet need and emerging new market can drive the growth of this market

Market Restraints

Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-smith-lemli-opitz-syndrome-market

Segmentation: Global Smith-Lemli-Opitz Syndrome Market

By Diagnosis

Molecular Genetic Testing
Antenatal Ultrasound
Others

By Treatment

Medication
Surgery

By Drugs

Cholesterol Supplementation
HMG CoA Reductase Inhibitor
Simvastatin
Atorvastatin Calcium
Others

By Route of Administration

Oral
Injectable

By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa

Key Developments in the Market:

In February 2018, According to the news published in Technical Network by Ellen Goldbaum for University at Buffalo that researcher from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that antioxidant combination therapy resulted in preventing the retinal degeneration that can occur in babies born with Smith-Lemli-Opitz Syndrome (SLOS). This reserach can excite other researcher to further investigate a potential treatment for SLOS patients.

Competitive Analysis:

Global Smith-Lemli-Opitz syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Smith-Lemli-Opitz syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global Smith-Lemli-Opitz syndrome market are Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Aurobindo Pharma, LUPIN, Micro Labs Ltd, Hetero, Biocon, Accord Healthcare, Merck & Co., Inc. and others